MUTE RECEIVES MAJOR REGULATORY APPROVALS

MUTE RECEIVES MAJOR REGULATORY APPROVALS

3 December 2014

Melbourne technology firm, Rhinomed (ASX:RNO) is pleased to announce that it has successfully completed the testing and technical documentation that has enabled its new novel snoring and sleep quality product – Mute™ to gain acceptance with the US Food and Drug Administration(FDA), European authority (CE Mark) and the Australian Therapeutic Goods Association (TGA).

Mute™ is an internal nasal dilator that increases airflow, which allows people to breathe more and snore less.